(R to L) EY's Ricardo Vilanova, Lila Bioscience's Molly Gibson, Merck's Iya Khalil, Insitro's Mary Rozenman, and Gallop Oncology's Luba Greenwood at BIO 2025. When Google shook the foundations of the ...
Australia's national science agency, CSIRO, together with its Australian National Soil Information System (ANSIS) partners, ...
Precise Bio has reported the first successful human implantation of its 3D-printed cornea implant, constructed of functional human eye cells cultured in a laboratory. The company described the ...
Miami-based founders Justin Elliott and Jahreem Samuels have scored an investment for their AI and blockchain-verified ...
CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging ...
Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. Down the line, Adagene could make up to $840 million in development and commercial ...
As prominent artificial intelligence (AI) researchers eye limits to the current phase of the technology, a different approach is gaining attention: using living human brain cells as computational ...
Shares of Cogent Biosciences (COGT) climbed ~120% in the premarket on Monday after the company disclosed encouraging late-stage trial data for its lead asset, bezuclastinib, against a form of ...
In October 2025, BioWorld tracked 252 clinical trial updates across phases I-III, roughly in line with September’s 230 but markedly higher than the 95 logged in August. Of those, 27 phase III studies ...
The key is to balance offense and defense. by Leandro DalleMule and Thomas H. Davenport More than ever, the ability to manage torrents of data is critical to a company’s success. But even with the ...
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the ...